The patterns of accumulation of cellular RNAs in cells infected with a wild-type and a mutant herpes simplex virus 1 lacking the virion host shutoff gene

Brunella Taddeo, Audrey Esclatine, and Bernard Roizman*

The Marjorie B. Kovler Viral Oncology Laboratories, University of Chicago, 910 East 58th Street, Chicago, IL 60637

Contributed by Bernard Roizman, September 30, 2002

Cellular RNA extracted from quiescent human foreskin fibroblasts harvested at 1, 3, 7, or 12 h after infection was profiled on Affymetrix HG-U95Av2 arrays designed to detect 12,626 unique human transcripts. We also profiled RNA extracted from cells harvested at 1 and 7 h after infection with a mutant lacking the gene ($\Delta U_{L}41$) encoding a protein (*vhs*) brought into cells by the virus and responsible for nonselective degradation of RNA early in infection. We report the following: (i) of the 12 tested genes, up-regulated at least 3-fold relative to the values of mock infected cells, 9 were confirmed by real-time PCR. The microchip assays analyses indicate that there were 475 genes up-regulated ≥3-fold. The up-regulated genes were clustered into 15 groups with respect to temporal pattern of transcript accumulation, and classified into 20 groups on the basis of their function. The preponderance of cellular genes up-regulated early in infection play a predominant role in transcription, whereas those upregulated at later times respond to intracellular stress or concern themselves with the cell cycle and apoptosis. (ii) The number of genes up-regulated early in infection was higher in cells infected with the $\Delta U_{L}41$ mutant. Conversely, more genes were downregulated late in infection with wild-type virus than with mutant viruses. Both observations are compatible with the known function of the U_L41 gene product early in infection and with degradation of cellular RNAs in the absence of replenishment by de novo transcription of cellular genes.

erpes simplex viruses 1 and 2 (HSV-1 and -2) have evolved an elaborate strategy to block host responses to infection. Of the numerous functions expressed by viral gene products designed to shut off the host, two are particularly important. A protein designated as virion host shutoff (vhs) (a product of the U_L41 ORF) that is brought into the cell as a component of the viral tegument causes the degradation of preexisting and newly transcribed mRNA during the first few hours after infection (1). At later times after infection, newly made vhs is sequestered and rendered inactive by another viral protein, α TIF (VP16) (2). Another protein made immediately after infection, the infected cell protein 27 (ICP27), the product of the α 27 ORF, contributes to the reduction in cellular mRNA levels by blocking pre-mRNA splicing (3). Late in infection, ICP27 shuttles between nucleus and cytoplasm, promotes the export of viral mRNAs (4), and no longer appears to block splicing (reviewed in ref. 5). The functions of ICP27 are not harmful to the virus. Of the four viral genes containing introns, three ($\alpha 0$, $\alpha 22$, and $\alpha 47$) are expressed immediately after infection, concurrently with the $\alpha 27$ gene. The fourth gene, U_L 15, is expressed late in infection at the time when ICP27 promotes mRNA export. The known functions of the UL41 and $\alpha 27$ gene products suggest that accumulation of cellular mRNA early in infection would be significantly reduced, and that even less cellular mRNA would be processed into mRNA and translated. Nevertheless, the known functions of these proteins would also predict that cellular transcripts could accumulate in larger amounts late in infection.

The predictions based solely on the basis of the known functions of viral gene products raise several important questions. On one hand, the interdiction of cellular gene expression early in infection raises the question whether the intent of the elaborate strategy is to block specific cellular responses that could block viral replication. Another scenario, equally plausible, given that viral mRNA is also subject to the same nucleolytic attack early in infection, is that cellular transcripts made at a very high rate could be expressed notwithstanding the efficacy of the blockade. On the other hand, the equally elaborate window of opportunity for cellular gene expression at mid or late times after infection raises the question whether the cellular takeover is complete, and hence the cell response inconsequential, or whether the virus induces the expression of specific cellular genes whose products it requires for its own use.

In the studies described here, we profiled cellular RNAs after infection to characterize transcriptional response to herpes simplex virus infection as a function of time after infection. DNA microarray technology provides a powerful tool to profile cellular responses to many environmental stimuli, including infections with a variety of viruses (6-9). For these studies, we have chosen GeneChip microarrays HG-U95Av2 (Affymetrix, Santa Clara, CA), containing probes representative of 12,626 human transcripts, to profile the RNA accumulating at different times after infection with wild-type virus or a mutant ΔU_{L} 41 lacking the gene encoding the vhs protein. Because of the nonselective degradation of RNA caused by vhs, we focused on genes up-regulated after HSV-1 infection. The studies were done on quiescent human foreskin fibroblasts (HFF) because they most closely resemble the human cells likely to be infected in vivo. Moreover, growth arrest induced by confluency and serum starvation could be expected to reduce transcriptional activity to the bare minimum necessary to keep the cells alive. Lastly, by selecting this system, we could compare our results with those obtained following human cytomegalovirus virus (HCMV) infection (9).

Materials and Methods

Cells and Viruses. Primary HFF cells were cultured in DMEM supplemented with 10% FCS. The stock of HSV-1(F), the prototype wild-type HSV-1 strain used in this laboratory, was prepared as follows: at 24 h after infection HEp-2 cells were harvested, rinsed, and suspended in ice-cold 0.4 M NaCl for 30 min. The cells were then centrifuged and the pellet discarded. The supernatant fluid was diluted 10-fold in serum-free medium (mixture 199) and stored at -80° C. The stock ΔU_L41 (mutant R2621; ref. 10) was prepared by the same procedure. All virus stocks were titered in Vero cells.

Abbreviations: HCMV, human cytomegalovirus; HFF, human foreskin fibroblasts; HSV-1, herpes simplex virus 1.

^{*}To whom correspondence should be addressed. E-mail: bernard@cummings. uchicago.edu.

Cell Infection. Confluent HF cells $(1 \times 10^7 \text{ cells in a } 150 \text{-cm}^2 \text{ flask})$ were stored for 7 days in the same (spent) medium and were then mock infected or exposed to 20 plaque-forming units (pfu) of HSV-1(F) or $\Delta U_L 41$ per cell for 90 min at 6°C in the spent medium. The inoculum was then replaced with 25 ml of the spent medium and the cultures shifted to 37°C (0 h) to synchronize the infection. Three independent infections with HSV-1(F) were carried out. The medium was removed from infected cells at 1, 3, 7, or 12 h after the shift to 37°C, and the cells were lysed *in situ* by the addition of 8 ml of TR Izol reagent (Life Technologies, Rockville, MD) and frozen at -80° C. The $\Delta U_L 41$ mutant-infected cells were harvested at 1 and 7 h after infection. Viral infection was confirmed by Northern analyses for the presence of the α 22 ORF transcripts (data not shown).

RNA Purification and Hybridization to GeneChip. Total RNA was purified from TRIzol suspension according to the manufacturer's instructions and then digested with DNase (Life Technologies), extracted with phenol-chloroform and precipitated with ethanol (Fisher) to remove contaminating DNA. The RNA samples were hybridized to Affymetrix HG-U95A array by the Functional Genomics Facility at the University of Chicago. Three different sets of arrays were used for the three independent experiments of HSV-1(F) infection.

Data Analysis. Chip data sets were analyzed with the Affymetrix GeneChip analysis software (Microarray Suite Version 5) and transformed to a Microsoft EXCEL file. Data were first sorted based on the *P* value that defines the presence or absence of the signal for each probe set (>0.06 = absent; <0.06 and >0.04 = marginal; <0.04 = present). In the present study, the *P* value has been changed to 0.08 to limit false-negatives. The intensity values of each gene present in at least one sample, including mock-infected cells, were extracted and recompiled. Fold increase for each gene was calculated with the aid of GENESPRING software (Version 4.2.1, Silicon Genetics, Mountain View, CA), using mock-infected cell data as baseline. Genes were assigned to specific functional groups with the aid of the Netaffx analysis center (www.affymetrix.com/analysis/index.affx).

Real-Time PCR. Total RNA (1 μ g) from mock-infected and HSV-1-infected cell samples was reverse transcribed with random hexamers and Multiscribe Reverse transcriptase (Applied Biosystems). cDNA quantities were normalized to 18S rRNA quantities (primers from Ambion, Austin, TX) obtained from the same plate. Real-time PCR primers were selected for each gene by using PRIMER EXPRESS software (Version 2.0, Applied Biosystems). Reactions were performed in a 50- μ l volume that included diluted cDNA sample, primers (1 μ g/ml), and SYBR Green PCR Master mix (Applied Biosystems) that contained nucleotides, AmpliTaq Gold DNA polymerase, and optimized buffer components. Real-time PCR reactions were performed on an Applied Biosystems Prism 7000 sequence detection system. Predicted cycle threshold (Ct) values were exported directly into EXCEL worksheets for analysis. After cycling, a melting curve was produced by slow denaturation of the PCR end products to validate the specificity of amplification. To compare mock and infected cell samples, relative changes in gene expression were determined using the $2^{-\Delta\Delta Ct}$ method as described (11, 12).

Results

Experimental Design. Differential expression of HFF genes during a 12-h interval after HSV-1 infection was investigated as described in *Materials and Methods*. Because the vhs protein, a component of the viral tegument, causes the degradation of preexisting and newly transcribed mRNA during the first few hours after infection (1), we focused on RNAs whose expression was up-regulated compared with that of mock-infected cells.

Table 1. Distribution of genes up-regulated in HSV-1-infec	ted
cells according to temporal pattern of RNA expression rela	ative
to those of mock-infected cells	

	Hours postinfection				HSV-1-infected/mock-infected							
Group	1	3	7	12	>2.0	>2.5	>3.0	>4.0	>5.0			
A	+	+	+	+	12	9	6	3	2			
В	+	+	+	-	12	5	4	1	0			
С	+	$^+$	-	-	30	18	14	8	4			
D	+	$^+$	-	+	2	1	0	1	0			
E	_	+	+	-	45	32	22	9	4			
F	-	$^+$	+	+	43	30	16	7	4			
G	-	-	+	+	64	61	62	42	30			
н	+	-	+	+	10	5	2	0	0			
I	+	-	+	-	13	12	8	6	5			
J	-	$^+$	-	+	16	10	8	3	1			
К	+	-	_	+	5	4	3	1	1			
L	+	-	-	-	120	93	75	50	38			
M	_	+	-	-	123	111	85	56	38			
N	_	_	+	-	111	115	75	88	70			
0	-	-	-	+	77	90	95	106	87			

 $+,\,$ Increased by the indicated ratio compared to mock-infected cells; –, absent or below the indicated ratio compared to mock-infected cells.

Three independent experiments were done, and the RNAs were analyzed on three different sets of GeneChips. To capture a truly representative snapshot of the RNAs accumulating in response to HSV-1 infection, cellular RNAs whose transcripts showed up-regulation at least in two of the three experiments were included in the final tally.

Time Course of Accumulation of Cellular Transcripts. Based on the RNA accumulation profile during the time course, the genes could be divided into 15 groups, from A to O (Table 1). The total number of genes up-regulated in HSV-1-infected cells from \geq 2-to \geq 5-fold relative to the corresponding value of mock-infected cells is also shown (Fig. 1). Several aspects of this table are of interest. Only a relatively small number of genes were up-regulated throughout the 12 h of study (group A). As expected, a larger number of genes was up-regulated at 7 or 12 h after



Fig. 1. Total number of up-regulated genes in HSV-1(F)-infected cells according to fold increase relative to mock-infected cells. The total number of genes for each ratio value was calculated based on the distribution of genes reported in Table 1.

Table 2. Number of up-regulated genes for each functional group

Functional group

Transcriptional factors and regulators	69
Signaling	36
Cell cycle	24
Oncogenesis	24
RNA processing and binding	24
Transport	20
Metabolism	19
Translation	15
Kinases	14
Enzymes general	13
DNA modification/replication	11
Structural proteins	10
Stress response/cell defense	9
Apoptosis	8
Ubiquitin	8
Neuronal	7
Cell adhesion	4
Growth factor	4
Miscellaneous	69
Unknown sequence/new proteins	87

infection compared with earlier time points. Nevertheless, even in the presence of vhs activity, a certain number of genes were up-regulated early in the infection (groups A–D), suggesting either that these RNAs were resistant to vhs or that the genes were transcribed at a very high level. Finally, the largest number of up-regulated genes accumulated at a single time point after infection (groups L–O). Indeed, they represented 80% of the total number of up-regulated genes at the \geq 5-fold level compared with those of mock-infected cells.

Validation of the results obtained with the array analysis by alternative techniques (see below for confirmation by real-time PCR) led us to consider all of the genes identified from groups A to O that were up-regulated \geq 3-fold relative to those of mock-infected cells. These genes were clustered in 20 groups on the basis of known function by using the GeneOntology database (Table 2). Some of the up-regulated genes for each functional group are listed in Table 3. The time after HSV-1 infection at which the highest level of the RNA was detected (Max fold increase) is indicated, as well as the modulation of these genes in cells infected with the ΔU_L 41 mutant virus of HCMV. The complete list of genes is reported in Table 5, which is published as supporting information on the PNAS web site, www.pnas.org.

Validation of Chip Data by Real-Time PCR. To validate the results obtained by microchip analyses, we selected 16 genes for confirmation by real-time PCR. These genes were chosen to be representative of a large range of ratios and different RNA accumulation profiles. The results are shown in Table 4 and Fig. 2. Although the sampling was limited, it helped establish the dimensions of the gene pool subject to further studies. The inclusion in Table 5 of all of the 475 genes up-regulated \geq 3-fold relative to corresponding genes in the control set was based on two main observations. (i) The genes showing a peak of induction <3-fold in HSV-1-infected cells compared with those of mock-infected cells showed no increase in real-time PCR assays [Serum response factor, Krit-1, Cyclin G- associated kinase, and Splicing factor SF3a60 (Table 4)]. Of the 12 remaining genes with a peak of induction >3-fold relative to controls, 75% were confirmed by real-time PCR. The remaining three genes (A20, Oct-1, and E2F1) yielded discordant results. (*ii*) GADD45 β , included among up-regulated genes, was up-regulated 3-fold relative to the values of mock-infected cells at a single time point (7 h) after infection. Real-time PCR showed an up-regulation at all of the time points tested with a peak at 7 h. The increase of GADD45 β mRNA, along with that of IEX-1 mRNA in wild-type virus-infected HFF, HeLa, or HEp-2 cells was further validated by Northern analyses (data not shown).

The Role of the HSV-1 U_L 41 Gene. U_L 41 gene product, the vhs protein, is responsible for the shutoff of cellular protein synthesis induced by HSV-1 early in infection. To analyze the host RNA transcriptional profile after HSV-1 infection in the absence of the vhs protein, HFF were infected with the $\Delta U_L 41$ mutant and total RNA was extracted at 1 and 7 h after infection and processed as described above. Genes whose RNA was up- or down-regulated in ΔU_L 41-infected cells relative to those of mock-infected cells were compared with those up- or down-regulated after infection with HSV-1(F). The observed patterns of cellular responses were consistent with the predicted effects of the degradation of RNA mediated by the vhs protein. Thus, a larger number of genes was specifically up-regulated very early after infection (1 h) in $\Delta U_L 41$ mutantinfected cells than in wild-type virus-infected cells (128 vs. 17; Fig. 3). The unexpected finding was that the large number of genes predicted to be down-regulated early in infection with wild-type virus actually occurred late in infection. As shown in Fig. 3, the number of down-regulated genes at 1 h after infection with wild-type or $\Delta U_L 41$ viruses was similar (29 vs. 33 and 35 genes in common). The difference becomes more pronounced at 7 h, where 292 genes were down-regulated in HSV-1(F)-infected cells as compared with 76 genes in ΔU_{L} 41 mutant-infected cells (Fig. 3). Moreover, there were numerous genes up-regulated in ΔU_L 41- but not in HSV-1(F)-infected cells; these are listed in Table 6, which is published as supporting information on the PNAS web site. The genes that were up-regulated after HSV-1(F) infection and also induced in ΔU_{L} 41 mutant-infected cells are listed in Tables 3 and 5. It is noteworthy that several RNAs up-regulated in HSV-1(F)infected cells were not modified in $\Delta U_L 41$ mutant-infected cells.

Discussion

No.

Several aspects of these studies are of particular interest.

(*i*) Of the 69 mRNAs encoding transcription factors and/or proteins involved in transcription regulation up-regulated in infected cells (Tables 3 and 5), many attained peak levels very early in infection (between 1 and 3 h). Furthermore, most of the small number of genes up-regulated throughout the 12-h time course (Table 1 A group) belong to this functional group.

(*ii*) Several of the genes shown to be up-regulated in this study have already been reported to be up-regulated after HSV-1 infection by measurement of RNA and/or protein levels. These include c-fos (13), HSP70 (14), or TGF- β (15). A previous report showed up-regulation of transcriptional factor and stress response genes after HSV-1 infection, using a different DNA array system (16). Most of these genes are induced in our system.

(*iii*) Several mRNAs encoding proteins with roles in cell cycle regulation and oncogenesis were up-regulated after HSV-1 infection (Tables 3 and 5). Because HSV-1 inhibits cell cycle progression (17), the significance of up-regulation of these genes requires further investigation. Similarly, HSV-1 has been reported to inhibit apoptosis induced by a wide variety of exogenous and endogenous inducers (18). At least eight up-regulated genes were classified as pro- or antiapoptotic. The specific role of these genes in HSV-1 replication needs to be elucidated.

(*iv*) HSV-1 induces a persistent NF- κ B nuclear translocation (19) as a result of the activation of the I κ B kinase (IKK) and degradation of I κ B α early in infection (20). After translocation

Table 3. Genes modulated by HSV-1(F): Comparison with ΔUL41 mutant and HCMV

Gamban Discription mechase Discription mechase Discription Model Discription Model Call Discription 0 <th></th> <th></th> <th>Max fold</th> <th>Time</th> <th></th> <th></th> <th></th> <th>.</th> <th>Max fold</th> <th>Time</th> <th></th> <th></th>			Max fold	Time				.	Max fold	Time		
XMX00 GLUDS GLUDS GLUDS Rel I U U U U <th>Genbank</th> <th>Description</th> <th>increase</th> <th>(h)</th> <th>∆UL41</th> <th>СМУ</th> <th>Genbank</th> <th>Description</th> <th>increase</th> <th>(h)</th> <th>∆UL41</th> <th>CWA</th>	Genbank	Description	increase	(h)	∆UL41	СМУ	Genbank	Description	increase	(h)	∆UL41	CWA
Modify all CADDIS space T	X68277	dual specificity phosphatase 1 (CL 100)	8.0	1	U	υ	J04111	c-iun proto oncogene (JUN)	6.6	1	U	D
AFCUSYDCARDON SenseCHARDCHAR	M60974	GADD45 alpha	7.4	7	-	D	V01512	cellular oncogene c-fos	c 17.6	1	Ū	Ū
Shifty Ex1 Set 2 F C V V <td< td=""><td>AF078077</td><td>GADD45 beta</td><td>c 13.3</td><td>7</td><td>-</td><td>U</td><td>K00650</td><td>c-fos protein</td><td>c 35.3</td><td>1</td><td>υ</td><td>U</td></td<>	AF078077	GADD45 beta	c 13.3	7	-	U	K00650	c-fos protein	c 35.3	1	υ	U
Arrong match match produce produce (produce) S.3 F C C C C </td <td>S81914</td> <td>IEX-1</td> <td>4.6</td> <td>7</td> <td>-</td> <td>U</td> <td>AF038362</td> <td>B-TFIID transcription factor-associated</td> <td>c 16.5</td> <td>3</td> <td>U</td> <td>U</td>	S81914	IEX-1	4.6	7	-	U	AF038362	B-TFIID transcription factor-associated	c 16.5	3	U	U
Appendix Instrume Control Contro Control Control <	AF069250	okadaic acid-inducible phosphoprotein	5.3	12	-	U	48002307	p300 protein Spf2-related CBP activator protein	4.2	3	-	U
XmirrApproxApproxApproxCCAAT See thering transpring fragmentsApproxApp	Apoptosis	near shock protein 70 (hsp70)	0.5	12	-		U80457	transcription factor SIM2 short form	4.0	3	-	U
ALGOSOZInclusion<	X98172	caspase 8	4.4	3	-	D	M37197	CCAAT-box-binding transcription factor	5.2	7	-	Ũ
All Y1160 uniadr to Bikl, (Ed.2 (Ka 1) 2.1 7 - 0 All Y1160 uniadro Di Rikl, (Ed.2 (Ka 1) 3.2 7 - 0 All Y1160 uniadro Di Rikl, (Ed.2 (Ka 1) 3.2 7 - 0 All Y1160 uniadro Di Rikl, (Ed.2 (Ka 1) 1.3 7 - 0 0 All Y1160 uniadro Di Rikl, (Ed.2 (Ka 1) 1.3 7 - 0 0 All Y1160 uniadro Di Rikl, (Ed.2 (Ka 1) 1.3 7 - 0 0 All Y1160 uniadro Di Rikl, (Ed.2 (Ka 1) 1.3 7 - 0	AI950382	phosphatidylserine receptor	4.1	7	-	U	X96381	ets variant gene 5	c 40	7	U	U
Cale optimizational definition of DMA banding 2 (2014) 33.2 7 - D Cale optimization of DMA banding 2 (2014) D 11000 Photomagnetic DMA banding 2 (2014) 33.2 7 - D X14600 battore FAX X 61.2 7 - U MAD23 BitShate Statewidt (2014) 0.1	Al971169	similar to BIML (Bcl2-like 11)	c 14.2	7	-	υ	X77956	inhibitor of DNA binding 1 (Id1)	26.2	7	-	D
Antenerse Selected Section 9 0 0 VEX00 MADD Selected Section 97 7	Cell cycle r	Hated bistone H2A family member ()	0 E	7		11	D13891	inhibitor of DNA binding 2 (Id-2H)	33.2	7	~	0
X1400 istans P(\(\lambda), maxmine P(\(\beta), Z) c V 0.00004 interplay fields (\(\beta), maxmine P(\(\beta), Z) C V </td <td>AI885852</td> <td>histone H2A family member O</td> <td>11.6</td> <td>7</td> <td>U</td> <td>U U</td> <td>M69043</td> <td>MAD-3 IkB-like activity</td> <td>17.7</td> <td>7</td> <td>_</td> <td>Ŭ</td>	AI885852	histone H2A family member O	11.6	7	U	U U	M69043	MAD-3 IkB-like activity	17.7	7	_	Ŭ
X2004b interaction for Argents X1340 contraction for Argents X1340 contraction for Argents X1340 contraction for Argents K1340 contraction for Argents K1340 interaction for Argents K14 K14 <td>X14850</td> <td>histone H2A.X</td> <td>c 12.3</td> <td>7</td> <td>-</td> <td>Ű</td> <td>AB020634</td> <td>nuclear factor of activated T-cells 5</td> <td>6.8</td> <td>7</td> <td>υ</td> <td>D</td>	X14850	histone H2A.X	c 12.3	7	-	Ű	AB020634	nuclear factor of activated T-cells 5	6.8	7	υ	D
UR805 profile phesphalae Wigh 7 9 0 D1665 Timescription fields (2) C B 7 - U UR02112 open indeparting profile 0 (RIG-1) 10.3 7 - U	X60484	histone H4 family, member E	5.1	7	-	D	X13403	oct-1 protein	3.8	7	-	U
AF D2-C10 cyclin D kandler grinnel-hae B C2 - D Mod2 FI T	U78305	protein phosphatase Wip1	7.0	7	+	U	D15050	transcription factor 8	c 15.8	7	-	U
Augustania Bartian Construction	AF 052102	cyclin D binding myb-like	9.8	12		U U	M62831	transcription factor ETR101	10	12	-	0
Ling 200 nuclear recopic updamily, group A. cn 01 i	Signaling	remobilisiona binding protein 6 (NDQ=1)	0 13.1	12	U	U	U71267	CCR4-NOT transcription complex, subunit 4	4.7	12	-	ŭ
Sel134CREM-bala <t< td=""><td>L13740</td><td>nuclear receptor subfamily 4, group A</td><td>c 10.1</td><td>1</td><td>-</td><td>U</td><td>X63741</td><td>early growth response 3 (pilot)</td><td>c 6.2</td><td>12</td><td>-</td><td>Ū</td></t<>	L13740	nuclear receptor subfamily 4, group A	c 10.1	1	-	U	X63741	early growth response 3 (pilot)	c 6.2	12	-	Ū
22487 111 Islammine receptor 4.1 3 0 0 W37000 HC-Faining transcriptor factor, X-box importance (Rec) X-box imp	S68134	CREM-beta	6.0	3	-	U	X59268	general transcription factor IIB	16.5	12	-	U
AL22309 interface neglectary, keto tanking 1 c b 1 015006 machen transcription tanks, keto tanking 1 c b 1 12 U UP175 mailour chusse profiles kinds 61 3 - U U	Z34897	H1 histamine receptor	4.1	3	U	D	W37606	HCF-binding transcription factor Zhangfei	4.8	12	-	U
Unter Sector And Sector And Sector And Sector	AL022398	interferon regulatory factor 6	3.1	3	~	D	U15306	nuclear transcription factor, X-box binding 1	C 15.4	12	0	D II
U2704 RAB27A (unit GTP-Insiding protein) 3.1 3 - U MC678 transcription factor C772 2 2 0 S4149 TGF Inside: any month response 6.6 3 - U MC6701 MC6701 4.8 3 - U MC6821 result regulated proteins gamma 4.2 7 - U AB00747 ZNF 2978 (LMA0414) 3.4 3.4 3 - U L12463 regulated for optomising animal 2 (GCS2) 6.1 7 - U U00110 BLC (ZNF51) 6.7 7 - U V10313 inderformatical developmental regulator (PCC) 6.5 1.2 - U U00110 BLC (ZNF51) 6.7 - U U01411 ZNF31 6.7 7 - U V17718 prim demonsmental developmental regulator (PCC) 6.5 7 - U U01410 ZNF311 1.2 7 - U V17717 prim demonsmental	U67156	nrogen-activated protein kinase 14	5.5	3	-	D	AB011165	thyroid bormone recentor-associated protein	9.9	12	-	U U
SP143 TGFE inductive early growth requised protein gramma 6.1 0.2 7 - U M20041 APRO1461 Kuppel-Hab ZHF Z/B C 1 3 - U MEGE2 growth requised protein gramma 6.2 7 - U U U V Finded ZHF C 1 3 - U L13463 resultator of C-protein signallarg 2(RGS2) 8.1 7 - U	U57094	RAB27A (small GTP-binding protein)	3.1	3	-	Ű	M76766	transcription factor (TFIIB)	c 27.2	12	-	Ű
ME0521ephone coeffor EphA2ephoneepi 227eUKuppelle Varpelle XP206.13.43eDL24564rane-associated whindholis (RAD)e14.47UUAD06794XPR-276 (MAOH4)3.43.43-UL24564ephine recoder DE PhA4C3.37-UAD06794ZPR-276 (MAOH4)3.41.	S81439	TGFB inducible early growth response	4.6	3	-	D	M62810	transcription factor A, mitochondrial	8.1	12	-	U
MABBE? growth regulated protein gamma 4.2 7 - U L23277 L-mry Lesion sequence Zn-15 reliable ZP/F C II 3.4 3.4 0 L23463 resultator of C-protein signaling 2 (RGS2) 6.1 7 U U AB00737 ZP 2076 (KRAA0H4) 3.4 3.4 0 3.4 0 J - U A200501 Interfaceon reliaded developmental regulator (FC-PR) C5.8 - U U00118 CE (2/2*51) 4.2 2.2 - U A200505 Interaction reliaded Sevelopmental regulator (FC-P) C5.8 - U U00118 CE (2/2*51) - U X78956 Interaction reliaded Sevelopmental regulator (FC-P) C5.8 - U U23118 Interaction reliaded Sevelopmental regulator (FC-P) C5.8 - U V7718 Interaction reliaded Sevelopmental regulator (FC-P) C5.8 7 - U U23137 N/2*16 (angle-stranded RAA binding) 0.4 12.3 12.4 U V17717 Interaction reliad	M59371	ephrin receptor EphA2	¢ 12.2	7		U	AF001461	Kruppel-like ZNF Zf9	4.8	3	-	D
Labes Tab. Skedenda of Mr. Baberik (MAU) C # 1.4 7 U U Ald Selection Comparison A.3 3 - U Labed optimization C G protein Signaling 7 (RCS) B.1 7 - U Ald Selection C Training C (RC) (Prot Sin) B.1 7 - U Labed optimization C G protein Singling 7 (RCS) B.1 1 - U U Diff Selection C (RC) (Prot Sin) B.1 7 - U Labed optimization C (RC) B.1 1 - U U U Diff Selection C (RC) B.1 B.1 - U U U Diff Selection C (RC) B.1 B.1 Diff Selection C (RC) B.1 Diff Selection C (RC) B.1 Diff Selection C (RC) Dif	M36821	growth regulated protein gamma	4.2	7	-	U	U22377	L-myc fusion sequence Zn-15 related ZNF	c 11	3	-	U
13866 optim necorpic fiph/4 6 43 1 2 - U U00115 6 C.G. (2017), 10, 10, 10, 10, 10, 10, 10, 10, 10, 10	L24564	ras-associated with diabetis (RAD)	C 411.4 8 1	7	U	11	AB007874	ZINF 297B (KIAA0414) Zinc finger C2H2 type domains	3.4 4 0	્ય	-	0
ACC005 12 interferon-related developmental regulator 1 (PCA) 16 12 - U U00410 ZMF130 51 1	L36645	ephrin receptor EphA4	c 34.3	12	-	Ŭ	U00115	BCL6 (ZNF51)	8.7	7	-	Ŭ
Y10313 indefenor-related developmental regulator 1 (PC-4) c U U00848 ZMP 130 C52 C12 c D X78565 inascin-C 3.1 3 - D L41813 broncolox gams in HOXA gams cluster 9.2 7 - D X78565 innascin-C 3.1 2 - D Mathematic and transcerve associated protein 7 - D V0703 NA mismatch repair protein MSH6 6.0 7 - D MSM processing functional (HXX) 7.5 12 - D V0730 NA mismatch repair protein MSH6 6.0 7 - U MSM poince MSM poince MSM poince MSM poince - D D MSM poince MSM poince <t< td=""><td>AC005192</td><td>interferon-related developmental regulator 1 (PC4)</td><td>16</td><td>12</td><td>-</td><td>U</td><td>U09410</td><td>ZNF 131</td><td>4.1</td><td>12</td><td>-</td><td>υ</td></t<>	AC005192	interferon-related developmental regulator 1 (PC4)	16	12	-	U	U09410	ZNF 131	4.1	12	-	υ
Cell administor Cell Administor D23118 ZM F61 D54118 ZM F61 D64 D L D VX7866 Innación C 3.1 3 - D UM 7718 Nonmolocu gran in HDXA gene clustar 0.2 7 - D DVM modification/Replication Nonmolocu gran in HDXA gene clustar 8.2 7 - U MV 7676 Nonmolocu gran in HDXA gene clustar 7.1 7 - U MS243 2M 5766 Innoncolocu gran in HDXA gene clustar 7.1 7 - U MS243 2M 5766 Innoncolocu gran in HDXA gene clustar 1.2 0 D MS243 2M 5766 Innoncolocu gran in HDXA gene clustar 1.2 U D D MS257 NA baci somma subuntar 2.2 U U D <td>Y10313</td> <td>interferon-related developmental regulator 1 (PC4)</td> <td>c 9.5</td> <td>12</td> <td>-</td> <td>U</td> <td>U09848</td> <td>ZNF139</td> <td>5.2</td> <td>12</td> <td>-</td> <td>D</td>	Y10313	interferon-related developmental regulator 1 (PC4)	c 9.5	12	-	U	U09848	ZNF139	5.2	12	-	D
Access and access associated protein 5.1 5.3 7.2 0 0/11/57 inflicit of the construction of the constr	Cell adhesi	on	2.4	2		D	D28118	ZNF 161	8.9	12	-	D
DNA modification?Replication Control Control PRA processing RNA binding proteins Control AF905913 chonosomain helicise DNA hinding protein 1 8.2 7 - U V13737 DNA mismach regular potein MSH6 6.0 7 - U SS83912 helterogeneous nuclear ribonuclooprotein A3 7.5 12 - D V0737 DNA mismach regular potein MSH6 6.0 7 - U V19756 ImPRPores protein A1 1 12.2 U D V0737 DNA polymerase gamma subunt 2 c 21.7 12 - U DS0322 ImPRPores protein A1 3 M 1 12 - U Growth factor J c 21.7 12 - U U A827665 septing factor, argninalserine-rich 4.3 12 - U J02404 thromodomain containing 2 homolog RING3 13.7 7 U U U U A8076928 mitchonorinal heosomal protein homologue 3.3 3 - U	1177718	ninin desmosome associated protein	5.1	12		0	M97676	homeobox gene in HOXA gene cluster	9.2 c 13.5	7	-	0
AF006313 chromodomain helicase DNA binding protein 18 8.2 7 - U M32284 Seques and se	DNA modifi	cation/Replication	0.0	.2		Ŭ	RNA proces	ssing/ RNA binding proteins	0 10.0	'		Ŭ
U7373 DNA mismach repair protein MSH6 6.0 7 - D S63912 hetrogeneous nuclear inbruiceprotein A3 7.5 12 0 D V00760 DNA hopoisamersal in Constraint 5.9 7.0 0.0 V07536 hetrogeneous nuclear inbruiceprotein 3 (MP-3) 3.1 12 0.0 D X00737 nucleoside phosphorylase PNP 5.9 7.0 0.0 V03032 mRNA splitcing factor protein A(MP-3) 3.1 12 0.0 AL096714 REV3-like (DNA polymersae parts) 5.9 12 - U V28521 similar to splicing factor protein formologue 3.3 3 12 - U Al02748 israulin-like growth factor 2 precursor 8.1 7 U U V128907 methorine aminopepidase 6.18 7 - U S78771 CPG Island-associated gene 5.8 12 - U U U V129907 methorine aminopepidase 6.8 7 - U S78771 CPG Island-associated gene 5.8 1 U U V10902 Sint A N <td>AF006513</td> <td>chromodomain helicase DNA binding protein 1</td> <td>8.2</td> <td>7</td> <td>-</td> <td>U</td> <td>M92843</td> <td>ZNF36 (single-stranded RNA binding)</td> <td>9.4</td> <td>7</td> <td>-</td> <td>D</td>	AF006513	chromodomain helicase DNA binding protein 1	8.2	7	-	U	M92843	ZNF36 (single-stranded RNA binding)	9.4	7	-	D
U0/260 DNA k by biosnersaes in price 7.1 7 - U X7PS 3 InfeN N-briding protein 3 (IM-3) 3.1 12 U D U30737 Ducleoside prospheryhorpiase PNP 5.9 7.2 - U D	U73737	DNA mismatch repair protein MSH6	6.0	7	-	D	S63912	heterogeneous nuclear ribonucleoprotein A3	7.5	12	-	D
XAD131 Inducessing prospin/produce rise C1 C2 C1 C1 C2 C1 C1 <thc1< th=""> <thc1< th=""> C1</thc1<></thc1<>	U07806	DNA topoisomerase I	7.1	7	-	0	X79536	hnRNPcore protein A1	12.3	12	U	D
AL096744 REV3-like (DNA polymerase zeta) 5.9 12 - D W28521 similar to splicing factor, arginina/serine-rich 4 4.3 12 - U Growth factor insulin-like growth factor 2 precursor 8.1 12 - U N28526 splicing factor, arginina/serine-rich 4 4.3 12 - U N3242 insulin-like growth factor 2 precursor 8.1 12 - U N25695 HL23 ribosomal protein homologue 3.3 3 - D V2605 prioritic in kinase 8.4 7 U U U29607 methorine aminopeptidase c12.8 12 U U M52027 protein kinase 6.4 7 U U U29607 methorine aminopeptidase c12.8 7 U U A6003791 carbohydrate sulfotansforase 1.5 U U W16quito amino protein (E2-EFF) 4.0 7 U U A6003701 carbohydrate sulfotansforase c 6.0 7 - U A60472 anguaporin 3 c 82.2 7 U U	U94703	DNA polymerase gamma subunit 2	5.9 c 21.7	12	-	U	D83032	mRNA splicing	5.4	12	-	D
Growth lactiveAnd SeriesSplein gladar proline/glutamine rich1.2 <th< td=""><td>AL096744</td><td>REV3-like (DNA polymerase zeta)</td><td>5.9</td><td>12</td><td>-</td><td>D</td><td>W26521</td><td>similar to splicing factor, arginine/serine-rich 4</td><td>4.3</td><td>12</td><td>-</td><td>Ū</td></th<>	AL096744	REV3-like (DNA polymerase zeta)	5.9	12	-	D	W26521	similar to splicing factor, arginine/serine-rich 4	4.3	12	-	Ū
J03242 insulin-like growth factor 2 precursor 8.1 12 P U Translation Kinase X5564 HL23 ribosomal protein homologue 3.3 3 3 0 0 D42040 bromodomain containing 2 homolog RING3 13.7 7 U U 48007928 methoinine aminopelidase c1.8 12.8 U U 48007928 S78771 CpG island-associated gene 8.4 7 U	Growth fact	or					A1827895	splicing factor proline/glutamine rich	13.4	12	-	U
Kinase Kinase Sköls4 HI23 nbosomal protein homologue 3.3 3.4 - D D42040 bromodornain containing 2 homolog RING3 13.7 7 U D AB00728 mictohondrial hbosomal protein S10 c11 7.6 U U D AB007391 mithon protein Kinase c12.8 12 U	J03242	insulin-like growth factor 2 precursor	8.1	12	-	U	Translation	I				_
Dackson Dackson <t< td=""><td>Kinase</td><td>bromodomain containing 2 bornolog PING3</td><td>13.7</td><td>7</td><td></td><td>п</td><td>X55954</td><td>HL23 ribosomal protein homologue mitochondrial ribosomal protein S10</td><td>3.3</td><td>3</td><td>-</td><td>D U</td></t<>	Kinase	bromodomain containing 2 bornolog PING3	13.7	7		п	X55954	HL23 ribosomal protein homologue mitochondrial ribosomal protein S10	3.3	3	-	D U
AF091395 similar to protein kinase 8.4 7 U Diguitin M59287 protein kinase 5.9 12 - U AJ010346 RING-H2 protein RNF6 6.8 7 - U M50287 protein kinase 5.9 12 - U M100346 RING-H2 protein RNF6 6.8 7 - U AB003791 Carbohydrate sulfotransferase 1 c.5.8 1 U V Transport V V AJ245434 apoliporotein receptor c.7.8 3 U V N74607 aquaporin 3 c.82.2 7 U U AF056214 cholesterol 25-hydroxylase c.6.0 7 - U AJ26418 golgi SNAP receptor complex member 1 4.8 12 - U V63793 S-adenosylmethionine decarboxylase 5.6 12 - U AJ264748 golgi SNAP receptor complex member 1 4.8 12 - U V83793 S-adenosylmethionine decarboxylase 5.6 12 - U Miscellaneous X2209 meringioma	S78771	CpG island-associated gene	25.4	7	Ű	U	U29607	methionine aminopeptidase	c 12.8	12	Ū	U
M5827 protein kinase 5.9 12 - U Al/0103/6 RING-H2 protein RINF6 6.8 7 - U Matabolist cabohydrate sulfotransferase 1 c.5.8 1 U U Matabolist wiguintic carrier protein (E2-EPF) 4.0 7 U U Al20379 cabohydrate sulfotransferase 1 c.5.8 3 U V Transport Al20352 low denskt jikoprotein receptor c.7.8 3 U U N74607 acyaporito a (for supportein receptor somplex member 1 4.8 12 U U V63793 S-adenosymethionine decarboxylase 1 3.8 7 - U AF047438 golgi SNAP receptor complex member 1 4.8 12 - U V63793 S-adenosymethionine decarboxylase 1 3.8 12 - U Niscellan=outcare NAS	AF091395	similar to protein kinase	8.4	7	Ū	D	Ubiquitin				-	
Metaolism M91670 ubiquito carrier protein (E2-EPF) 4.0 7 U U V AB003791 carbohydrate sulfotransferase 1 c.8.1 3 U U Transport c.82.2 7 U U U L00352 low density lipoprotein receptor c.7.8 3 - D Y10032 serum/glucocorticoid regulated kinase 4.0 7 U D AF058214 cholesteroi 25-hydroxylase c.6.0 7 - U N86013 AEC transporter protein c.7.0 12 - U U38661 AEC transporter protein 4.8 12 - U S70154 acetyl-Coenzyme A acetyltransferase 2 c.7.5 12 - U AL132712 rucear RN export factor 1 (NXF1) 9.4 12 - U V08111 protein phosphatase inhibitor 2 (PPP1R2) 15.8 7 - U AE00027 congulation factor 1 (INSUE of Insule	M59287	protein kinase	5.9	12	-	U	AJ010346	RING-H2 protein RNF6	6.8	7	-	U
AB003/91 carbonydrate sulfictansferase 1 c.5.8 1 U U Inamport A246434 apolipoprotein receptor c.7.8 3 U U V10032 serum/glucocorticoid regulated kinase 4.0 7 U D AF052914 cholesterol 25-hydroxylase c.6.0 7 - U U38661 ABC transporter protein c.7.0 12 - U W63793 S-adenosylmethionine decarboxylase 1 3.8 7 - U AF067438 golgi SNAP receptor complex member 1 4.8 12 - U W63791 acethy-Coenzyme A acetyltransferase 2 c.7.5 12 - U AF0747898 golgi SNAP receptor complex member 1 4.8 12 - U W16311 protein phosphatase inhibitor 2 (PPP1R2) 10.8 12 - U Microana AF046059 cytokine receptor related protein 4 (CYTOR4) 3.4 3 - U M200277 DAP-1 alpha 15.8 7 - U AF080227 embryonic ectoderm development 4.6 3 - U U	Metabolism		5.0				M91670	ubiquitin carrier protein (E2-EPF)	4.0	7	U	U
Approximation 0.0.1	AB003791 A 1245434	carbohydrate suitotransferase 1 apolipoprotein M	C 5.8	1	1	0	N74607	anuanorin 3	c 82 2	7		u.
AF059214 cholesterol 25-hydroxytase c 6.0 7 - U U38361 ABC transporter protein c 7.0 12 - U V653793 S-adenosylmethionine decarboxytase 1 3.8 7 - U AF047438 golgi SNAP receptor complex member 1 4.8 12 - U V653793 S-adenosylmethionine decarboxylase 1 3.8 7 - U AF047438 golgi SNAP receptor complex member 1 4.8 12 - U V06811 protein phosphatase inhibitor 2 (PPP1R2) 10.8 12 - U Miscellaneous Neuronal - V Miscellaneous X8209 meringioma (disrupted in balanced translocation) 3.8 1 U D AF0400277 DAP-1 alpha 15.8 7 - D J02931 coagutation factor III tissue factor c15.6 3 - U U19523 GTP cyclohydrolase 1 c 6.8 7 - U AF0400227 embryonic ectoderm development 4.6 3 - U U19523 GTP cyclohydrolase 1 c 6.8 </td <td>L00352</td> <td>low density lipoprotein receptor</td> <td>c 7.8</td> <td>3</td> <td>-</td> <td>D</td> <td>Y10032</td> <td>serum/glucocorticoid regulated kinase</td> <td>4.0</td> <td>7</td> <td>ŭ</td> <td>D</td>	L00352	low density lipoprotein receptor	c 7.8	3	-	D	Y10032	serum/glucocorticoid regulated kinase	4.0	7	ŭ	D
W63793 S-adenosylmethionine decarboxylase 1 3.8 7 - U AF047438 g0gi SNAP receptor complex member 1 4.8 12 - U S70154 acetyl-Coenzyme A acetyltransferase 2 c 7.5 12 - U AJ132712 mudear RNA export factor 1 (NXF1) 9.4 12 - U W18511 protein phosphatase inhibitor 2 (PPTR2) 10.8 12 - U Miscellanaout 3.8 1 U D Neuront AB00277 DAP-1 alpha 15.8 7 - U AF060059 colagulation factor III tissue factor c15.6 3 - U AB00277 DAP-1 alpha 15.8 7 - U J02931 coagulation factor III tissue factor c1.6 3 - U U19523 GTP cyclohydrolase 1 c 6.8 7 - U U26067 insulin induced gene 1 (NSIG1) c 5.4 3 - U U19523 GTp cyclohydrolase 1 c 6.8 7 - U U26081 senaphorin-III (Hsema-I) A.8 3 - <	AF059214	cholesterol 25-hydroxylase	c 6.0	7	-	υ	U83661	ABC transporter protein	c 7.0	12	-	U
S70154 acetyl-Coenzyme A acetyltransferase 2 c 7.5 12 - D Al132712 nuclear RNA export factor 1 (NXF1) 9.4 12 - U U68111 protein phosphatase inhibitor 2 (PPP1R2) 10.8 12 - U Miscellaneous Neuronal . X82209 meningioma (disrupted in balanced translocation) 3.8 1 U D AB000277 DAP-1 alpha 15.8 7 - D J02931 coagulation factor III tissue factor c15.6 3 - D U19523 GTP cyclohydrolase 1 c 6.8 7 - U U96876 insulin induced gene 1 (INSIG1) c5.4 3 - D U19523 GTP cyclohydrolase 1 c 6.8 7 - U U96876 insulin induced gene 1 (INSIG1) c5.4 3 - D Oncogenesis c C 1.1 7 - U L26081 semaphorin-III (Hsema-I) 4.8 3 - D U77735 pim-2 oncogene c 16.1 7 - U L26081 semaphorin	W63793	S-adenosylmethionine decarboxylase 1	3.8	7	-	U	AF047438	golgi SNAP receptor complex member 1	4.8	12	-	U
Obsenting protein prospirates inhibitor 2 (PP Ir2) 10.8 12 - 0 meringioma (disrupted in balanced translocation) 3.8 1 U D Neuronal X82209 cytokine receptor related protein 4 (CYTOR4) 3.4 3 - U AB000277 DAP-1 alpha 15.8 7 - D Jugg91 coagulation factor III tissue factor c15.6 3 - D L07919 distal-less homeobox domain c55.3 7 - U Ve6807 embryonic ectoderm development 4.6 3 - D U19523 GTP cyclohydrolase I c68 7 - U U96876 insulin induced gene 1 (INSIG1) c5.4 3 - D Oncogenesis - - U U96876 insulin induced gene 1 (INSIG1) c5.4 3 - D V17735 pin-2 oncogene c16.1 7 - U L036083 RNA transcript from U17 small nucleolar RNA c15.2 7 - U	S70154	acetyl-Coenzyme A acetyltransferase 2	c 7.5	12	-	D	AJ132712	nuclear RNA export factor 1 (NXF1)	9.4	12	-	U
Main of the decision of	M21154	s-adenosylmethionine decarboxylase	10.8	12	-	11	X82209	meningioma (disrupted in balanced translocation)	3.8	1		р
AB000277 DAP-1 alpha 15.8 7 - D J02931 coagulation factor III tissue factor c 15.6 3 - D L07919 distal-less homeobox domain c 55.3 7 - U AF060227 embryonic ectoderm development 4.6 3 - U U19523 GTP cyclohydrolase I c 6.8 7 - U U96876 insulin induced gene 1 (INSIG1) c 5.4 3 U D U061849 similar to rat neuronal pentraxin 1 .4.6 7 - U U96876 insulin induced gene 1 (INSIG1) c 5.4 3 U D AB024401 inhibitor of growth family, member 1 (p33) c 7.1 7 - U AL050089 bromodomain adjacent to zin finger domain, 1A c 14.4 7 - U M30309 v-erb-b2 erythroblastic leukernia v-onc homolog 3 c 16.5 7 - U AL050089 RNA transcript from U17 small nucleolar RNA c 15.2 7 - U AB015335 cutaneo	Neuronal		0.0	12		Ŭ	AF046059	cytokine receptor related protein 4 (CYTOR4)	3.4	3	-	Ŭ
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	AB000277	DAP-1 alpha	15.8	7	-	D	J02931	coagulation factor III tissue factor	c 15.6	3	-	D
U19523 GTP cyclohydrolase I c 6.8 7 - U U96876 insulin induced gene 1 (NSIG1) c 5.4 3 - D U61849 similar to rat neuronal pentraxin 1 4.6 7 - D U12128 protein tyrosine phosphatase, non-receptor type 13 3.3 3 U D AB024401 inhibitor of growth family, member 1 (p33) c 7.1 7 - U L26081 semaphorin-III (Hsema-1) 4.8 3 - U M34309 v-erb-b2 cerythroblastic leukemia v-onc homolog 3 c 16.5 7 - U L30426 DNA segment on chromosome X and Y 3.4 7 - U M434309 v-erb-b2 cerythroblastic leukemia v-onc homolog 3 c 16.5 7 - U D31485 AD0-ribosylation factor-like 6 interacting protein 8.6 12 - U M64347 fibroblast growth factor receptor 3 c 13.5 12 - U D83702 cryptochrome 1 (photolyase-like) c 7.4 12 - U D90070 phorbol-12-myristate-13-acetate-induced protein c 19.7 12 -	L07919	distal-less homeobox domain	c 55.3	7	-	U	AF080227	embryonic ectoderm development	4.6	3	-	υ
Obstand similar for afficiency as printaxin for afficiency of the formal perinaxin formal perinaxin for afficiency of the formal perinaxin perinaxin formal perinaxin perinaxin formal perina perinaxin perinaxin formal perina perinaxin formal perina perinaxin perinaxin formal perina perinaxin formal perina perinaxin perinaxin formal perina perinaxin perinaxin perina perina	U19523	GTP cyclohydrolase I	c 6.8	7	-	U	U96876	insulin induced gene 1 (INSIG1)	c 5.4	3		D
Conception Conception <thconception< th=""> Conception Concepti</thconception<>	Opcogenes	similar to rat neuronal pentraxin 1	4.0		-	D	126081	semanborin-III (Hsema-I)	c 3.3 4.8	3	0	D
U77735 pim-2 oncogene c 16.1 7 - U L03426 DNA segment on chromosome X and Y 3.4 7 - U M34309 v-erb-b2 erythrobtastic leukemia v-onc homolog 3 c 16.5 7 - U AJ006835 RNA transcript from U17 small nucleolar RNA c 15.2 7 - U AB015345 cutaneous T-cell lymphoma-assoc.tumor antigen 5.5 12 - U D31885 ADP-ribosylation factor-like 6 interacting protein 8.6 12 - U AB014579 meningioma expressed antigen 5 4.2 12 - D AB02(179 HEXIM1 protein c 17.8 12 - U D90070 phorbol-12-myristate-13-acetate-induced protein 1 c 19.7 12 - U AJ010014 M96A protein, putative DNA binding protein c 6.9 12 - U AF051160 protein tyrosphatase type IVA, member 1 c 19.7 12 - U AJ010014 M96A protein, putative DNA binding protein c 6.9 12 - U <td>AB024401</td> <td>inhibitor of growth family, member 1 (p33)</td> <td>с 7.1</td> <td>7</td> <td>-</td> <td>υ</td> <td>AL050089</td> <td>bromodomain adjacent to zinc finger domain. 1A</td> <td>c 14.4</td> <td>7</td> <td>-</td> <td>Ű</td>	AB024401	inhibitor of growth family, member 1 (p33)	с 7.1	7	-	υ	AL050089	bromodomain adjacent to zinc finger domain. 1A	c 14.4	7	-	Ű
M34309 v-erb-b2 erythroblastic leukernia v-onc homolog 3 c 16.5 7 - U AJ069835 RNA transcript from U17 small nucleolar RNA c 15.2 7 - U AB015345 cutaneous T-cell lymphoma-assoc.tumor antigen 5.5 12 - U D31885 ADP-ribosylation factor-like 6 interacting protein 8.6 12 - U AB015345 fibroblast growth factor roceptor 3 c 13.5 12 - U D83702 cryptochromer 1 (photobasse-like) c 7.4 12 - U AB014579 meningioma expressed antigen 5 4.2 12 - D Ab01714 HEXIM1 protein c 17.8 12 - U D90070 phorbol-12-myristate-13-acotate-induced protein 1 c 19.7 12 - U AJ010014 M96A protein, putative DNA binding protein c 6.9 12 - U AF051160 protein tyrosine phosphatase type IVA, member c 8.6 12 - U AL080188 similarity to nuclear proteins (SRK ritch) c 7.5 12 -	U77735	pim-2 oncogene	c 16.1	7	-	U	L03426	DNA segment on chromosome X and Y	3.4	7	-	υ
ABD15345 cutaneous T-cell lymphoma-assocutumor antigen 5.5 12 - U D31885 ADP-ribosylation factor-like 6 interacting protein 8.6 12 - U M64347 fibroblast growth factor receptor 3 c13.5 12 - U D83702 cryptochrome 1 (photolyase-like) c7.4 12 - U AB014579 meningioma expressed antigen 5 4.2 12 - D AB02179 HEXIM1 protein c17.8 12 - U AB014579 photob-12-myristate-13-acotate-induced protein 1 c19.7 12 - U AJ010014 M96A protein, putative DNA binding protein c6.9 12 - U AF051160 protein tyrosine phosphatase type IVA, member 1 4.2 12 U D D45132 PR domain containing 2 4.4 12 - D X75042 rel proto-oncogene c.8.6 12 - U AJ080176 similarity to nuclear proteins (SRK ritch) c.7.5 12 - D <td>M34309</td> <td>v-erb-b2 erythroblastic leukernia v-onc homolog 3</td> <td>c 16.5</td> <td>7</td> <td>-</td> <td>U</td> <td>AJ006835</td> <td>RNA transcript from U17 small nucleolar RNA</td> <td>c 15.2</td> <td>7</td> <td>-</td> <td>U</td>	M34309	v-erb-b2 erythroblastic leukernia v-onc homolog 3	c 16.5	7	-	U	AJ006835	RNA transcript from U17 small nucleolar RNA	c 15.2	7	-	U
Monosover monocols grown nactor receptor 5 C 13.5 1.2 - 0 Destruct chrono response C 7.4 1.2 - 0 AB014579 meningioma expressed antigen 5 4.2 1.2 - D AB021179 HEXIM1 protein c 17.8 1.2 - U AB014579 phobol-12-wristate 1-3 acotate/-induced protein 1 c 19.7 1.2 - U AJ010014 M96A protein, putative DNA binding protein c 6.9 1.2 - U AF051160 protein tyrosine phosphatase type IVA, member 1 4.2 1.2 U D D45132 PR domain containing 2 4.4 1.2 - D X75042 rel proto-oncogene c 8.6 1.2 - U AL080186 similarity to nuclear proteins (SRK ritch) c 7.5 1.2 - D	AB015345	cutaneous T-cell lymphoma-assoc.tumor antigen	5.5	12	-	U	D31885	ADP-ribosylation factor-like 6 interacting protein	8.6	12	-	U
D90070 phorbol-12-myristate-13-acetate-induced protein c 19.7 2 - U AJ010014 M96A protein, putative DNA binding protein c 6.9 12 - U AF051160 protein tyrosine phosphatase type IVA, member 1 4.2 12 U D D45132 PR domain containing 2 4.4 12 - D X75042 rel proto-oncogene c 8.6 12 - U AJ080186 similarity to nuclear proteins (SRK ritch) c 7.5 12 - D X75042 rel proto-oncogene c 8.6 12 - U AJ080186 similarity to nuclear proteins (SRK ritch) c 7.5 12 - D	NI04347 AB014570	merobiasi growin racion receptor 3 menongioma expressed antigen 5	4.2	1∠ 12	-	D D	AB021179	HEXIM1 protein	с 17 Я	12		U U
AF051160 protein tyrosine phosphatase type IVA, member 1 4.2 12 U D D45132 PR domain containing 2 4.4 12 - D X75042 rel proto-oncogene c 8.6 12 - U AL080186 similarity to nuclear proteins (SRK ritch) c 7.5 12 - D X70042 rel proto-oncogene c 8.6 12 - U X700410 c 7.5 12 - D	D90070	phorbol-12-myristate-13-acetate-induced protein 1	c 19.7	12	-	Ŭ	AJ010014	M96A protein, putative DNA binding protein	c 6.9	12	-	Ű
X75042 rel proto-oncogene c 8.6 12 - U II AL000186 similarity to nuclear proteins (SRK ritch) c 7.5 12 - D V7004 c 8.6 12 - U II AL000186 similarity to nuclear proteins (SRK ritch) c 7.5 12 - D V7004 c 8.6 12 - U II AL000186 similarity to nuclear proteins (SRK ritch) c 7.5 12 - D	AF051160	protein tyrosine phosphatase type IVA, member 1	4.2	12	U	D	D45132	PR domain containing 2	4.4	12	-	D
	X75042	rel proto-oncogene	c 8.6	12	-	U	AL080186	similarity to nuclear proteins (SRK ritch)	c 7.5	12	-	D

The "c" in front of the fold change indicates that the transcript was scored absent in mock-infected cells. In column Δ UL41, genes modulated by Δ UL41 mutant infection: —, no change or absent compared to mock-infected cells; U, up-regulated compared to mock-infected cells. In column CMV, genes modulated by CMV infection: U, up-regulated; D, down-regulated compared to mock-infected cells.

to the nucleus, NF- κ B activates a variety of genes encoding adhesion molecules, inflammatory and chemotactic cytokines, proteins involved in stress response and apoptosis, growth factors, and transcription factors (21). As result of the NF- κ B activation mediated by HSV-1, several genes reported to be NF- κ B targets were found to be up-regulated by microarrays (Tables 3 and 5). These genes are dispersed among the 19 functional groups and include Bcl-xL, HIAP-1, IEX-1, and GADD45 β among the apoptotic and stress related genes; c-myc, c-jun, I κ B α , and NF- κ B p105 as transcriptional factors/ oncogenes; or TNF- α and TNF-related proteins as part of signal transduction pathways. The significance of up-

Table 4. Correlation of selected genes by real-time PCR

	GenBank			Real-tin	ne PCR	Microarray				
No.	accession no.	Gene	1*	3*	7*	12*	1*	3*	7*	12*
1	V01512	c-fos	256	16	36	4.2	18	3.9	12	9
2	AF078077	GADD45b	4.7	3.1	17	3.6	_	_	13	_
3	Z80776	Histone H2A-G	2.1	1.3	3	0.7	1.2	—	3.5	
4	L19779	Histone H2A-O	1.1	1.4	2.9	0.7	2.3	1	12	6
5	X14850	Histone H2A.X	0.6	0.9	7.2	1.4	_	_	12	_
6	X60484	Histone H4-E	1.4	1.5	3.9	1.2	1.1	—	3.1	
7	S81914	IEX-1	12	14	8.9	1.9	2.8	3.1	4.6	
8	X77956	ld-1	2.1	3.2	12	2.1	_	3.2	11	
9	D13891	Id-2H	3.1	2.7	9.1	2.7	1.6	1.5	6.5	5
10	M59465	A20	2.3	1.7	1.4	1.6	_	—	—	9
11	X13403	Oct-1	1.4	1.1	1.7	1.2	_	—	3.6	4
12	M96577	E2F-1	0.5	0.1	0	0	11	11	_	—
13	J03161	Serum response factor	1	1	0.3	0.1	1.3	2.5	1.6	2
14	U90268	Krit-1	0.6	0.4	0.4	0.2	_	2.5	—	
15	D88435	Cyclin G-associated kinase	0.4	0.3	0.1	—	—	2.7	1.8	2
16	X81789	Splicing factor SF3a60	0.3	0.4	0.2	0.1	1.9	1.6	2.8	

-, No change or absent as compared to mock-infected cells.

*Hours postinfection.

regulation of some of these genes is dealt with elsewhere (B.T. and B.R., unpublished work; T.-R. Luo, B.T., and B.R., unpublished work).

(v) The apparent decrease in the accumulation of transcripts late in infection with wild-type virus suggests that vhs is still active or that the results of its nucleolytic attack are still detectable later than expected. The synergistic activities of vhs, which degrades RNA, and ICP27, which inhibits the splicing and the export of cellular RNA, are responsible for the lack of cellular RNA pool reconstruction, resulting in a limitation of the cell defense response and a protection of the virus. However, there is also the possibility that in the absence of *de novo* transcription, the existing RNA decays and the rate of decay depends on the properties of the mRNAs. Furthermore, the



Fig. 2. Real-time PCR analysis of selected genes whose expression was modulated in microarray profiling by HSV-1. Fold change (expressed as log ratio) observed by microarray analysis at the peak of induction and by real-time PCR at the same time for 16 selected genes. The dashed line corresponds to a 3-fold increase in the accumulated RNAs of infected cells compared with those of mock-infected cells.

observation that several cellular genes whose mRNAs were up-regulated in HSV-1(F)-infected cells were found not to be up-regulated or even completely absent in ΔU_L 41-infected cells could be at least in part explained by the biological properties of the mutant virus, such as the slower replication profile compare with wild-type HSV-1 (10).

(*vi*) Modulation of cellular gene expression in HFF infected with HCMV was reported recently (9). Table 3 identifies the genes up-regulated in HSV-1(F)-infected cells that are upor down-regulated in HCMV-infected cells (www.molbio. princeton.edu/labs/shenk/browneetal2001/). Although both studies were done with the same Affymetrix microarrays, the analyses of the data were done with different software (9). Of the total of 135 cellular genes that overlap between HCMV and HSV-1, 43 were down-regulated and 92 were up-regulated. The genes are scattered among the most functional groups but are particularly prevalent in the groups comprising transcriptional factors and signaling. It is noteworthy that five of the seven overlapping genes in the group comprising RNA processing factors are down-regulated.

The next steps in the analysis of cellular responses to herpes simplex virus infection are: (i) confirmation that the changes observed in accumulation of transcripts results in a consequent accumulation of the relative protein products; and (ii) evaluation



Fig. 3. Venn diagrams showing the distribution of differentially regulated genes during infection with HSV-1(F) or $\Delta U_L 41$ mutant relative to those of mock-infected cells. (A) Up-regulated genes. (B) Down-regulated genes.

of the impact of the up-regulated genes on the outcome of viral infection.

We thank the University of Chicago Functional Genomics Facility and Dr. Xinmin Li for support with data analyses, Dr. Chris Dyanov for initial support with the microarray hybridizations, Sunil Advani for helpful

- 1. Karr, B. M. & Read, G. S. (1999) Virology 264, 195-204.
- Lam, Q., Smibert, C. A., Koop, K. E., Lavery, C., Capone, J. P., Weinheimer, S. P. & Smiley, J. R. (1996) *EMBO J.* 15, 2575–2581.
- 3. Hardwicke, M. A. & Sandri-Goldin, R. M. (1994) J. Virol. 68, 4797-4810.
- 4. Sandri-Goldin, R. M. (1998) Genes Dev. 12, 868-879.
- Roizman, B. & Knipe, D. M. (2001) in *Virology*, eds. Knipe, D. M. & Howley, P. M. (Lippincott, Philadelphia), pp. 2399–2459.
- Geiss, G. K., Bumgarner, R. E., An, M. C., Agy, M. B., van 't Wout, A. B., Hammersmark, E., Carter, V. S., Upchurch, D., Mullins, J. I. & Katze, M. G. (2000) *Virology* 266, 8–16.
- Cuadras, M. A., Feigelstock, D. A., An, S. & Greenberg, H. B. (2002) J. Virol. 76, 4467–4482.
- Geiss, G. K., Salvatore, M., Tumpey, T. M., Carter, V. S., Wang, X., Basler, C. F., Taubenberger, J. K., Bumgarner, R. E., Palese, P., Katze, M. G. & Garcia-Sastre, A. (2002) *Proc. Natl. Acad. Sci. USA* 99, 10736–10741.
- 9. Browne, E. P., Wing, B., Coleman, D. & Shenk, T. (2001) J. Virol. 75, 12319–12330.
- 10. Poon, A. P. & Roizman, B. (1997) Virology 229, 98-105.

discussion, and Weiran Zhang for technical support. We also thank Dr. Beatrice Fineschi and the Biological Sciences Collegiate Divisions for making the real-time PCR machine available. These studies were aided by National Cancer Institute Grants CA78766, CA71933, CA83939, CA87661, and CA88860 and grants from the U.S. Public Health Service. A.E. is a recipient of a fellowship from the Association pour la Recherche sur le Cancer (ARC France).

- 11. Livak, K. J. & Schmittgen, T. D. (2001) Methods 25, 402-408.
- 12. Pfaffl, M. W. (2001) Nucleic Acids Res. 29, E45-E45.
- Gieroba, Z. J., Zhu, B.-S., Blessing, W. W. & Wesselingh, S. L. (1995) Brain Res. 675, 329–332.
- 14. Phillips, B., Abravaya, K. & Morimoto, R. I. (1991) J. Virol. 65, 5680-5692.
- Mendez-Samperio, P., Hernandez, M. & Ayala, H. E. (2000) J. Interferon Cytokine Res. 20, 273–280.
- Khodarev, N. N., Advani, S. J., Gupta, N., Roizman, B. & Weichselbaum, R. R. (1999) Proc. Natl. Acad. Sci. USA 96, 12062–12067.
- 17. Ehmann, G. L., McLean, T. I. & Bachenhiemer, S. L. (2000) Virology 267, 335–349.
- 18. Galvan, V. & Roizman, B. (1998) Proc. Natl. Acad. Sci. USA 95, 3931-3936.
- Patel, A., Hanson, J., McLean, T. I., Olgiate, J., Hilton, M., Miller, W. E. & Bachenheimer, S. L. (1998) *Virology* 247, 212–222.
- Amici, C., Belardo, G., Rossi, A. & Santoro, M. G. (2001) J. Biol. Chem. 276, 28759–28766.
- 21. Pahl, H. L. (1999) Oncogene 18, 6853-6866.